Does the media refer more to BTAI or COYA?

In the previous week, Coya Therapeutics had 1 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 2 mentions for Coya Therapeutics and 1 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 0.00 equaled Coya Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioXcel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BDTX or BTAI?

In the previous week, Black Diamond Therapeutics had 11 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 12 mentions for Black Diamond Therapeutics and 1 mentions for BioXcel Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.47 beat BioXcel Therapeutics' score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioXcel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BNR or BTAI?

BioXcel Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 1,085.47%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts rate AADI or BTAI?

BioXcel Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 1,085.47%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BioXcel Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

BioXcel Therapeutics (BTAI) Competitors

$0.93 +0.03 (+2.91%)

As of 08/10/2026 04:00 PM Eastern

Compare

BTAI vs. PCSC, COYA, BDTX, BNR, and AADI

Should you buy BioXcel Therapeutics stock or one of its competitors? BioXcel Therapeutics's main competitors and comparable companies include Perceptive Capital Solutions (PCSC), Coya Therapeutics (COYA), Black Diamond Therapeutics (BDTX), Burning Rock Biotech (BNR), and Aadi Bioscience (AADI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioXcel Therapeutics compare to Perceptive Capital Solutions?

BioXcel Therapeutics (NASDAQ:BTAI) and Perceptive Capital Solutions (NASDAQ:PCSC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

In the previous week, BioXcel Therapeutics had 1 more articles in the media than Perceptive Capital Solutions. MarketBeat recorded 1 mentions for BioXcel Therapeutics and 0 mentions for Perceptive Capital Solutions. BioXcel Therapeutics' average media sentiment score of 0.00 equaled Perceptive Capital Solutions'average media sentiment score.

Company	Overall Sentiment
BioXcel Therapeutics	Neutral
Perceptive Capital Solutions	Neutral

30.7% of BioXcel Therapeutics shares are owned by institutional investors. 3.7% of BioXcel Therapeutics shares are owned by company insiders. Comparatively, 22.1% of Perceptive Capital Solutions shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Perceptive Capital Solutions has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Perceptive Capital Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%
Perceptive Capital Solutions	N/A	-2.70%	-0.84%

Perceptive Capital Solutions has lower revenue, but higher earnings than BioXcel Therapeutics. Perceptive Capital Solutions is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	44.77	-$69.90M	-$5.75	N/A
Perceptive Capital Solutions	N/A	N/A	$840K	-$0.06	N/A

BioXcel Therapeutics presently has a consensus price target of $11.00, indicating a potential upside of 1,085.47%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe BioXcel Therapeutics is more favorable than Perceptive Capital Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Perceptive Capital Solutions	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioXcel Therapeutics has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Perceptive Capital Solutions has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

Summary

BioXcel Therapeutics beats Perceptive Capital Solutions on 8 of the 14 factors compared between the two stocks.

How does BioXcel Therapeutics compare to Coya Therapeutics?

BioXcel Therapeutics (NASDAQ:BTAI) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

In the previous week, Coya Therapeutics had 1 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 2 mentions for Coya Therapeutics and 1 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 0.00 equaled Coya Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioXcel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 3.7% of BioXcel Therapeutics shares are owned by insiders. Comparatively, 6.1% of Coya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Coya Therapeutics has higher revenue and earnings than BioXcel Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	44.77	-$69.90M	-$5.75	N/A
Coya Therapeutics	$7.95M	13.69	-$21.23M	-$1.15	N/A

BioXcel Therapeutics has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

BioXcel Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 1,085.47%. Coya Therapeutics has a consensus target price of $15.33, suggesting a potential upside of 230.46%. Given BioXcel Therapeutics' higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Coya Therapeutics has a net margin of -266.10% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%
Coya Therapeutics	-266.10%	-55.86%	-48.86%

Summary

Coya Therapeutics beats BioXcel Therapeutics on 11 of the 15 factors compared between the two stocks.

How does BioXcel Therapeutics compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Black Diamond Therapeutics has higher revenue and earnings than BioXcel Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.63	$22.37M	-$0.75	N/A
BioXcel Therapeutics	$640K	44.77	-$69.90M	-$5.75	N/A

Black Diamond Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%

In the previous week, Black Diamond Therapeutics had 11 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 12 mentions for Black Diamond Therapeutics and 1 mentions for BioXcel Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.47 beat BioXcel Therapeutics' score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioXcel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Black Diamond Therapeutics currently has a consensus price target of $9.83, indicating a potential upside of 396.63%. BioXcel Therapeutics has a consensus price target of $11.00, indicating a potential upside of 1,085.47%. Given BioXcel Therapeutics' higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than Black Diamond Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Black Diamond Therapeutics has a beta of 3.28, suggesting that its stock price is 228% more volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Summary

Black Diamond Therapeutics beats BioXcel Therapeutics on 12 of the 16 factors compared between the two stocks.

How does BioXcel Therapeutics compare to Burning Rock Biotech?

Burning Rock Biotech (NASDAQ:BNR) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by company insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BioXcel Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 1,085.47%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, BioXcel Therapeutics had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 1 mentions for BioXcel Therapeutics and 0 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.00 equaled BioXcel Therapeutics'average media sentiment score.

Company	Overall Sentiment
Burning Rock Biotech	Neutral
BioXcel Therapeutics	Neutral

Burning Rock Biotech has higher revenue and earnings than BioXcel Therapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.48	-$7.92M	-$0.82	N/A
BioXcel Therapeutics	$640K	44.77	-$69.90M	-$5.75	N/A

Burning Rock Biotech has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Burning Rock Biotech has a net margin of -11.57% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%

Summary

BioXcel Therapeutics beats Burning Rock Biotech on 8 of the 15 factors compared between the two stocks.

How does BioXcel Therapeutics compare to Aadi Bioscience?

Aadi Bioscience (NASDAQ:AADI) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Aadi Bioscience has higher revenue and earnings than BioXcel Therapeutics. Aadi Bioscience is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.69	-$65.76M	-$2.35	N/A
BioXcel Therapeutics	$640K	44.77	-$69.90M	-$5.75	N/A

BioXcel Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 1,085.47%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BioXcel Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, BioXcel Therapeutics had 1 more articles in the media than Aadi Bioscience. MarketBeat recorded 1 mentions for BioXcel Therapeutics and 0 mentions for Aadi Bioscience. Aadi Bioscience's average media sentiment score of 0.00 equaled BioXcel Therapeutics'average media sentiment score.

Company	Overall Sentiment
Aadi Bioscience	Neutral
BioXcel Therapeutics	Neutral

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aadi Bioscience has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Aadi Bioscience has a net margin of -246.06% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%

Summary

Aadi Bioscience beats BioXcel Therapeutics on 8 of the 15 factors compared between the two stocks.

Get BioXcel Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BTAI vs. The Competition

Export

Metric	BioXcel Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$27.84M	$3.70B	$7.02B	$12.98B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.16	9.09	269.19	24.72
Price / Sales	44.77	1,255.18	588.76	97.77
Price / Cash	N/A	44.95	28.89	37.42
Price / Book	-0.21	17.66	11.27	6.42
Net Income	-$69.90M	-$13.25M	$3.45B	$347.03M
7 Day Performance	7.82%	5.36%	3.56%	2.49%
1 Month Performance	13.50%	-1.74%	-0.58%	-1.04%
1 Year Performance	-85.50%	61.36%	77.52%	23.22%

BioXcel Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BTAI BioXcel Therapeutics	1.7588 of 5 stars	$0.93 +2.9%	$11.00 +1,085.5%	-77.0%	$27.84M	$640K	N/A	90	News Coverage Upcoming Earnings
PCSC Perceptive Capital Solutions	0.119 of 5 stars	$11.95 flat	N/A	N/A	$97.48M	N/A	N/A	N/A
COYA Coya Therapeutics	2.0425 of 5 stars	$4.09 +0.1%	$15.33 +275.4%	-23.7%	$95.72M	$7.95M	N/A	6	News Coverage Upcoming Earnings
BDTX Black Diamond Therapeutics	2.9979 of 5 stars	$1.68 -2.3%	$9.83 +487.1%	-17.5%	$95.41M	N/A	N/A	90	Positive News Earnings Report Analyst Revision Gap Up
BNR Burning Rock Biotech	0.6653 of 5 stars	$8.71 -1.6%	N/A	+59.2%	$91.61M	$514.43M	N/A	1,390	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BTAI) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioXcel Therapeutics (BTAI) Competitors

BTAI vs. PCSC, COYA, BDTX, BNR, and AADI

How does BioXcel Therapeutics compare to Perceptive Capital Solutions?

Summary

How does BioXcel Therapeutics compare to Coya Therapeutics?

Summary

How does BioXcel Therapeutics compare to Black Diamond Therapeutics?

Summary

How does BioXcel Therapeutics compare to Burning Rock Biotech?

Summary

How does BioXcel Therapeutics compare to Aadi Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI vs. The Competition

BioXcel Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioXcel Therapeutics (BTAI) Competitors

BTAI vs. PCSC, COYA, BDTX, BNR, and AADI

How does BioXcel Therapeutics compare to Perceptive Capital Solutions?

Does the media favor BTAI or PCSC?

Do insiders & institutionals believe in BTAI or PCSC?

Is BTAI or PCSC more profitable?

Which has stronger earnings & valuation, BTAI or PCSC?

Do analysts prefer BTAI or PCSC?

Which has more volatility & risk, BTAI or PCSC?

Summary

How does BioXcel Therapeutics compare to Coya Therapeutics?

Does the media refer more to BTAI or COYA?

Do institutionals & insiders hold more shares of BTAI or COYA?

Which has preferable valuation & earnings, BTAI or COYA?

Which has more risk & volatility, BTAI or COYA?

Do analysts prefer BTAI or COYA?

Is BTAI or COYA more profitable?

Summary

How does BioXcel Therapeutics compare to Black Diamond Therapeutics?

Which has preferable valuation and earnings, BDTX or BTAI?

Is BDTX or BTAI more profitable?

Does the media refer more to BDTX or BTAI?

Do analysts recommend BDTX or BTAI?

Do insiders and institutionals have more ownership in BDTX or BTAI?

Which has more risk & volatility, BDTX or BTAI?

Summary

How does BioXcel Therapeutics compare to Burning Rock Biotech?

Do institutionals & insiders hold more shares of BNR or BTAI?

Do analysts prefer BNR or BTAI?

Does the media refer more to BNR or BTAI?

Which has stronger earnings and valuation, BNR or BTAI?

Which has more volatility & risk, BNR or BTAI?

Is BNR or BTAI more profitable?

Summary

How does BioXcel Therapeutics compare to Aadi Bioscience?

Which has stronger earnings & valuation, AADI or BTAI?

Do analysts rate AADI or BTAI?

Does the media favor AADI or BTAI?

Do institutionals & insiders have more ownership in AADI or BTAI?

Which has more volatility and risk, AADI or BTAI?

Is AADI or BTAI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI vs. The Competition

BioXcel Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools